Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002 Nov-Dec;4(6):420-3.
doi: 10.1111/j.1524-6175.2002.01641.x.

ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence

George L Bakris  1 , Matthew Weir
Affiliations
Review

ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence

George L Bakris et al. J Clin Hypertens (Greenwich). 2002 Nov-Dec.

Abstract

Although angiotensin-converting enzyme inhibitors are frequently used as antihypertensive agents to lower blood pressure and slow progression of nephropathy in patients with type 2 diabetes, evidence of their efficacy has been drawn primarily from small trials with surrogate end points. No adequately powered, long-term trials have tested their effects to reduce the incidence of hard end points, such as progression to end-stage renal disease or even doubling of serum creatinine in the population of patients with nephropathy from type 2 diabetes. While the results of angiotensin-converting enzyme inhibitor trials from nondiabetic causes and even type 1 diabetes may be extrapolated to the patient with nephropathy associated with type 2 diabetes, the hard evidence is not available. This review critically evaluates the limited evidence in support of angiotensin-converting enzyme inhibitors as renal-protective agents in people with type 2 diabetes.

PubMed Disclaimer

References

    1. US Renal Data System. USRDS 1999 Annual Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1999.
    1. Lewis EJ, Hunsicker LG, Bain, RP , et al. The effect of angiotensin‐converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–1462. - PubMed
    1. Mogensen CE. Preventing end‐stage renal disease. Diabetes Med. 1998;15(suppl 4):S51–S56. - PubMed
    1. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin‐converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med. 1995;99:497–504. - PubMed
    1. Ravid M, Lang R, Rachmani R, et al. Long‐term renoprotective effect of angiotensin‐converting enzyme inhibition in non‐insulin‐dependent diabetes mellitus. A 7‐year follow‐up study. Arch Intern Med. 1996;156:286–289. - PubMed

MeSH terms

Substances